GlassScriptPhysician profile
Stacey Youngblood
NPI 1114531902
$976.16
in general payments reported to CMS, 2019-2025
9 companies · $250 in 2025
The $250 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $49.51 · 2022: $138 · 2023: $220 · 2024: $318 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $788.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $788.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $416.04 | 2022-2025 | Farxiga, Breztri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $164.58 | 2025 | Caplyta |
| Abbvie INC. | $161.95 | 2021-2024 | |
| Exact Sciences Corporation | $87.42 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $46.48 | 2024 | Mounjaro, Zepbound |
| Organon LLC | $38.47 | 2025 | Nexplanon |
| Novo Nordisk INC | $27.98 | 2024 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.69 | 2023 | Jardiance |
| Genentech USA, INC. | $12.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Youngblood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.